Cargando…

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

Pancreatic neuroendocrine carcinoma (panNEC) is a rare disease. The rearrangements of neurotrophic tropomyosin receptor kinase (NTRK) genes are oncogenic. And in the existed literatures, the prevalence of NTRK3 was only 0.1% in neuroendocrine tumors. NTRK inhibitor was approved for refractory and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Wen-Chi, Chen, Ming-Huang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871888/ https://www.ncbi.nlm.nih.gov/pubmed/36703785 http://dx.doi.org/10.3389/fonc.2022.1031396

Ejemplares similares

The First Reported Case of Neurotrophic Tyrosine Receptor Kinase Fusion-Positive Thymoma Treated Successfully With Entrectinib
por: Salame, Hassan, et al.
Publicado: (2021)

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Platelet Activation in High D-Dimer Plasma Plays a Role in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Mutant Lung Adenocarcinoma
por: Lee, Meng-Jung, et al.
Publicado: (2022)

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas
por: Stravodimou, Athina, et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021)

Association of Polymorphisms in Inflammation Genes With the Prognosis of Advanced Non-Small Cell Lung Cancer Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Zhang, Xuelin, et al.
Publicado: (2022)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
por: Breitenecker, Kristina, et al.
Publicado: (2023)

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
por: Feng, Yiyi, et al.
Publicado: (2021)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report
por: Otsu, Yukiko, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

3D Ultrasound-Guided Photoacoustic Imaging to Monitor the Effects of Suboptimal Tyrosine Kinase Inhibitor Therapy in Pancreatic Tumors
por: Claus, Abigail, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook
por: Miles, Brittany, et al.
Publicado: (2021)

Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma
por: Tang, Tin-Yun, et al.
Publicado: (2021)

Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
por: Taban, Hakan, et al.
Publicado: (2022)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
por: Tian, Zhichao, et al.
Publicado: (2020)

Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors
por: Gerson-Gurwitz, Adina, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023)

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study
por: Chang, Qing, et al.
Publicado: (2021)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Transformation From Adenocarcinoma to Pleomorphic Carcinoma as an Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Nishimatsu, Kanako, et al.
Publicado: (2021)

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
por: Khan, Muhammad, et al.
Publicado: (2020)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
por: Deng, Jun, et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jv6jhm98viaf6coekmvkqnhvch